30-Year-Old Antibiotic Offers Hope for Patients With Huntington's Disease
WebMD News Archive
HDSA spokeswoman Joyce Hammel agrees. "This is very exciting, because it
is the first time we have seen anything delay the onset of disease and increase
life expectancy in an animal model," she tells WebMD. "We are hoping
that several discoveries like this will result in a synergistic approach to the
cure of HD." The cocktail approach appears the most likely, she says, even
though there is only one gene that causes the disease, because there is a very
complex progression from the gene to actual cell death and symptoms.
Huntington's disease is caused by a genetic disorder that prompts nerve cell
death in the region of the brain that controls movement. A little over a year
ago, Friedlander and colleagues reported that an enzyme called caspase-1 is
activated in the brains of humans and mice with the disease, and that blocking
caspase function delays disease onset and mortality in mice. The Harvard
researchers used minocycline in their most recent studies because it is known
to inhibit caspase-1 and caspase-3.
The antibiotic was found to significantly slow Huntington's disease
progression in the mouse model, but Friedlander says it is not yet clear why.
"We don't exactly know why minocycline works, but it is not the antibiotic
effect," he says. "We believe there are other properties involved, but
we don't know what they do."
While he agrees the findings are exciting, Ross would not speculate on when
an effective therapy might be available for the treatment of Huntington's
disease. "I am very hopeful that we will soon see some sort of therapy, but
I wouldn't want to say when," he says. "We still have a lot to
- Huntington's disease is a genetic disorder that causes progressive mental
and physical degeneration, eventually resulting in death.
- Researchers have found that the antibiotic minocycline slows the
progression of Huntington's disease in mice, but they are unsure how it
- Trials in humans are expected to begin soon, and researchers hope
treatments will become available that may be used before the onset of symptoms
in those who know they will develop the disease.